To all, more info from BW:
BW0041 OCT 22,1996 5:17 PACIFIC 08:17 EASTERN
( BW)(THERAGENICS)(THRX) Theragenics Corp. Reports Record Revenue
And Earnings for Third quarter 1996
Business Editors & Medical Writers
ATLANTA--(BUSINESS WIRE)--Oct. 22, 1996--Theragenics Corp.
(NASDAQ:THRX), the Atlanta based cancer treatment producer,
today announced revenues and earnings for the third quarter ending
Sept. 30, 1996.
Revenues for the quarter were $3,144,297 compared to
$1,926,456, a 63 percent growth over the same period last year. Net
income increased 118 percent to $917,894 from $421,106 with earnings
per share improving to $0.07 versus $0.04 in the prior year.
For the nine months ended Sept. 30, 1996, revenues were $8,669,188
versus $5,672,565, a 53 percent improvement over the first nine
months last year. Net income grew 106 percent to $2,449,870 from
$1,187,609 with earnings per share of $0.20 versus $0.10.
Commenting on the quarter's performance, Christine Jacobs,
president and CEO, said, "This quarter's outstanding revenues are due
in part to several events. First, this spring, we have benefited
from heightened media attention to seeding as a viable treatment
option for early stage prostate cancer. Secondly, we implemented
marketing initiatives to take advantage of our improved production
capabilities. Lastly, customers and patients alike, continue to
embrace the concept of TheraSeed(R) for the treatment of prostate
cancer."
During the quarter the Company continued the expansion of its
plant and equipment. Construction on its cyclotron facility was
completed, the testing of the third cyclotron was finalized and
material is now being produced. Cyclotron number four was safely
delivered to Buford and is now being installed.
Theragenics Corp., based in Norcross, Ga., is the manufacturer
of TheraSeed, a rice-sized device used in the treatment of
localized prostate cancer with a one-time, minimally-invasive
procedure. For additional information on the company, call
Theragenics' Investor Relations Department at (800)998-8479. The
Company's common stock is traded on the NASDAQ stock exchange under
the symbol THRX.
-0-
*T
Theragenics Corporation
Consolidated Statement Of Operations
Three Months Ended Nine Months Ended
Sept. 30, Sept. 30, Sept. 30, Sept. 30,
1996 1995 1996 1995
Revenues $3,144,297 $1,926,456 $8,669,188 $5,672,565
Net Income $ 917,894 $ 421,106 $2,449,870 $1,187,609
Earnings Per
Common Share $ 0.07 $ 0.04 $ 0.20 $ 0.10
Weighted Average
Shares Outstanding 12,298,440 11,937,322 12,220,313 11,826,326
*T
--30--eb/ny*
CONTACT: Theragenics Corp.
Ron Warren, (800)998-8479 or 770/381-8338 |
